2022-07-05-世界卫生组织-Immunization_United_Kingdom_of_Great_Britain_and_Northern_Ireland_2022_country_profile_16页_354kb

WHO and UNICEF estimates of immunization coverage for the United Kingdom of Great Britain and Northern Ireland are based on national data, child health information systems, and adjusted with independent denominators often, resulting in high coverage rates for various vaccines. Coverage is generally consistent at 90-95% for most vaccines, though estimates for periods before 2015 (like 2010-2012) are lacking empirical support. The COVID-19 pandemic in 2020 caused noted declines in some years, but coverage remains high. Key points:

• BCG vaccine: No available coverage estimates for the 2010-2021 period.
• DTP1 and DTP3 vaccines: Coverage is high, ranging from 93-98%, but empirical data is not accepted in some years due to underestimation by child health information systems. COVID-19 impacts noted in 2020 data, with declines referenced by Public Health England.
• Pol3 vaccine (third dose of polio): High coverage (93-95%) estimated with grade of confidence R+ D+, indicating support from reported data and adjusted denominators. COVID-19 disruptions noted for 2020.
• IPV1 vaccine (inactivated polio): Coverage exists from 2015 onwards; estimates lack empirical data in earlier years (2015 and later high, around 94-98%).
• MCV1 and MCV2 vaccines (measles doses): Consistently high (84-93% for MCV1, similar for MCV2), with grade of confidence R+ D+, affected by COVID-19 in 2020 and challenges in other years.
• RCV1 vaccine: Coverage derived from MCV1 estimates, high (91-94%) with R+ D+ confidence.
• HepBB vaccine (hepatitis B): No data available for the period.
• HepB3 vaccine: Coverage introduced in 2017 for hexavalent vaccine; estimates from 2019 show 93% with R+ D+ confidence, noting quality variations.
• Hib3 vaccine: High coverage (92-95%), with R+ D+ confidence, COVID-19 impact noted in 2020.
• RotaC vaccine: Data starts from 2015; coverage estimates around 90%, with GoC R+ D+ but limiting observations on source compatibility.
• PcV3 vaccine (pneumococcal conjugate): High coverage (91-94%), affected by COVID-19 in some years, with GoC R+ D+.

Estimates have limitations due to varying data quality and potential underestimation from administrative systems. Previous years' data are available at the provided links.